Have a personal or library account? Click to login
Assessing the Impact of COVID-19 Vaccination Programs on the Reduction of COVID-19 Cases: A Systematic Literature Review Cover

Assessing the Impact of COVID-19 Vaccination Programs on the Reduction of COVID-19 Cases: A Systematic Literature Review

Annals of Global Health
Volume 90 (2024): Issue 1
By: Brightwell Sibanda and  Budi Haryanto  
Open Access
|Jul 2024

References

  1. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020;382:1969–1973. 10.1056/NEJMp2005630.
    Back to article
  2. Forni G, Mantovani A. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ. 2021;28:626–639. 10.1038/s41418-020-00720-9.
    Back to article
  3. Dubé E. Addressing vaccine hesitancy: The crucial role of healthcare providers. Clin Microbiol Infect. 2017;23:279–280. 10.1016/j.cmi.2016.11.007.
    Back to article
  4. Dooling K, Marin M, Wallace M, et al. The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69:1657–1660. 10.15585/mmwr.mm695152e2.
    Back to article
  5. Mathieu E, Ritchie H, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19). Our World Data. 2020. Accessed October 31, 2023. https://ourworldindata.org/coronavirus.
    Back to article
  6. Cohen J. Shots of hope. Science. 2020;370:1392–1394. 10.1126/science.370.6523.1392.
    Back to article
  7. Forman R, Shah S, Jeurissen P, Jit M, Mossialos E. COVID-19 vaccine challenges: What have we learned so far and what remains to be done? Health Policy. 2021;125:553–567. 10.1016/j.healthpol.2021.03.013.
    Back to article
  8. European Medicine Agency. COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine’s benefits currently still outweigh risks Update. Eur Med Agency. 2021. Accessed October 31, 2023. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits.
    Back to article
  9. Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An update. Cureus. 2020;12:e7423. 10.7759/cureus.7423.
    Back to article
  10. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;324:782. 10.1001/jama.2020.12839.
    Back to article
  11. WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19. March 11, 2020. Accessed October 31, 2023. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
    Back to article
  12. WHO. COVID-19 Epidemiological Update. 2023.
    Back to article
  13. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. 10.1186/2046-4053-4-1.
    Back to article
  14. Liu Y, Procter SR, Pearson CA, et al. Assessing the impacts of COVID-19 vaccination programme’s timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries. BMC Med. 2023;21(85). 10.1186/s12916-023-02784-z.
    Back to article
  15. Bello-Chavolla OY, Antonio-Villa NE, Valdés-Ferrer SI, et al. Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: A retrospective analysis of national surveillance data. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2023;129:188–196. 10.1016/j.ijid.2023.01.040.
    Back to article
  16. McNamara LA, Wiegand RE, Burke RM, et al. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: An ecological analysis of national surveillance data. Lancet Lond Engl. 2022;399:152–160. 10.1016/S0140-6736(21)02226-1.
    Back to article
  17. Pattni K, Hungerford D, Adams S, et al. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. BMC Infect Dis. 2022;22:270. 10.1186/s12879-022-07239-z.
    Back to article
  18. Dunbar E. Reduction in COVID-19 patients requiring mechanical ventilation following implementation of a national COVID-19 vaccination program - Israel, December 2020–February 2021. MMWR Morb Mortal Wkly Rep. 2021;70:326–328. 10.15585/mmwr.mm7009e3.
    Back to article
  19. Steele MK, Couture A, Reed C, et al. Estimated number of COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in the US, December 2020 to September 2021. JAMA Netw Open. 2022;5:e2220385. 10.1001/jamanetworkopen.2022.20385.
    Back to article
  20. Shim E. Projecting the impact of SARS-CoV-2 variants and the vaccination program on the fourth wave of the COVID-19 pandemic in South Korea. Int J Environ Res Public Health. 2021;18. 10.3390/ijerph18147578.
    Back to article
  21. Homan T et al. Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: A one-year retrospective cohort study. Sci Rep. 2022;12:18597. 10.1038/s41598-022-23235-4.
    Back to article
  22. Kayano T. Evaluating the COVID-19 vaccination program in Japan, 2021 using the counterfactual reproduction number. Sci Rep. 2023;13:17762. 10.1038/s41598-023-44942-6.
    Back to article
  23. Chen X, Huang H, Ju J, Sun R, Zhang J. Impact of vaccination on the COVID-19 pandemic in U.S. states. Sci Rep. 2022;12:1554. 10.1038/s41598-022-05498-z.
    Back to article
  24. Tonnara G, Piselli P, Cimaglia C, et al. The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022;28:1636–1643. 10.1016/j.cmi.2022.06.026.
    Back to article
  25. Childs L, Dick DW, Feng Z, Heffernan JM, Li J, Röst G. Modeling waning and boosting of COVID-19 in Canada with vaccination. Epidemics. 2022;39:100583. 10.1016/j.epidem.2022.100583.
    Back to article
  26. Vaishya R, Sibal A, Malani A, et al. Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workers-A multicenter cohort study. Diabetes Metab Syndr. 2021;15:102306. 10.1016/j.dsx.2021.102306.
    Back to article
  27. Mancuso M, Eikenberry SE, Gumel AB. Will vaccine-derived protective immunity curtail COVID-19 variants in the US? Infect Model. 2021;6:1110–1134. 10.1016/j.idm.2021.08.008.
    Back to article
  28. Pérez-Then E, Miric M, Qian H-Z, et al. Population-level effectiveness of an inactivated whole-virion COVID-19 vaccine: A test negative case-control study in the Dominican Republic. Open Forum Infect Dis. 2023;10. 10.1093/ofid/ofad075.
    Back to article
  29. Spreco A, Dahlström Ö, Jöud A, et al. Effectiveness of the BNT162b2 mRNA vaccine compared with hybrid immunity in populations prioritized and non-prioritized for COVID-19 vaccination in 2021–2022: A naturalistic case-control study in Sweden. Vaccines. 2022;10. 10.3390/vaccines10081273.
    Back to article
  30. Wang R, Wang J, Hu T, Zhou X-H. Population‐level effectiveness of COVID‐19 vaccination program in the United States: Causal analysis based on structural nested mean model. Vaccines. 2022;10. 10.3390/vaccines10050726.
    Back to article
  31. Dunbar E, Godbout E, Pryor R, Rozycki HJ, Bearman G. Impact of coronavirus disease 2019 (COVID-19) vaccination program on healthcare worker infections in an academic hospital. Infect Control Hosp Epidemiol. 2022;43:680–681. 10.1017/ice.2021.62.
    Back to article
  32. Link-Gelles R. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5-and XBB/XBB.1.5-related sublineages among immunocompetent adults - Increasing Community Access to Testing Program, United States, December 2022–January 2023. MMWR Morb Mortal Wkly Rep. 2023;72:119–124. 10.15585/mmwr.mm7205e1.
    Back to article
  33. Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. Lancet Microbe. 2021;2:e279–e280. 10.1016/S2666-5247(21)00069-0.
    Back to article
  34. Vasireddy D, Vanaparthy R, Mohan G, Malayala SV, Atluri P. Review of COVID-19 variants and COVID-19 vaccine efficacy: What the clinician should know? J Clin Med Res. 2021;13(6):317–325. 10.14740/jocmr4518.
    Back to article
  35. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–594. 10.1056/NEJMoa2108891.
    Back to article
  36. Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol. 2022;7. 10.1038/s41564-021-01053-0.
    Back to article
  37. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020:NEJMoa2034577. 10.1056/NEJMoa2034577.
    Back to article
  38. Singh C, Naik BN, Pandey S, et al. Effectiveness of COVID-19 vaccine in preventing infection and disease severity: A case-control study from an Eastern State of India. Epidemiol Infect. 2021;149(e224):1–9. 10.1017/S0950268821002247.
    Back to article
  39. BIN MOHD IQBAL MT, Imran SA, Tye GJ, Zaman WK, Nordin F. COVID-19 vaccination effectiveness: A review in early vaccine adopters in Asian Countries. Eur Rev Med Pharmacol Sci. 2022;26(13). 10.26355/eurrev_202207_29216.
    Back to article
  40. Self WH. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions — United States, March–August 2021. MMWR Morb Mortal Wkly Rep. 2021;70. 10.15585/mmwr.mm7038e1.
    Back to article
  41. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385. 10.1056/NEJMoa2108891.
    Back to article
  42. Chi W-Y, Li Y-D, Huang H-C, et al. COVID-19 vaccine update: Vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci. 2022;29:82. 10.1186/s12929-022-00853-8.
    Back to article
  43. Kayano T, Ko Y, Otani K, Kobayashi T, Suzuki M, Nishiura H. Evaluating the COVID-19 vaccination program in Japan, 2021 using the counterfactual reproduction number. Sci Rep. 2023;13. 10.1038/s41598-023-44942-6.
    Back to article
  44. Alkhafaji DM, Al Argan RJ, Albahrani S, et al. The impact of vaccination against SARS-CoV-2 virus on the outcome of COVID-19 disease. Infect Drug Resist. 2022;15:3477–3489. 10.2147/IDR.S365179.
    Back to article
  45. Wells AU. COVID-19 Vaccine efficacy over time: Severe disease in hospitalized patients. Radiology. 2024;310:e233340. 10.1148/radiol.233340.
    Back to article
  46. Tonnara G, Piselli P, Cimaglia C, et al. The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. Clin Microbiol Infect. 2022;28:1636–1643. 10.1016/j.cmi.2022.06.026.
    Back to article
  47. Link-Gelles R, Levy ME, Natarajan K, et al. Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 Sublineage periods. JAMA Netw Open. 2023;6:e232598. 10.1001/jamanetworkopen.2023.2598.
    Back to article
  48. Bello-Chavolla OY, Antonio-Villa NE, Valdés-Ferrer SI, et al. Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: A retrospective analysis of national surveillance data. Int J Infect Dis. 2023;129:188–196. 10.1016/j.ijid.2023.01.040.
    Back to article
  49. Sadarangani M, Abu Raya B, Conway JM, et al. Importance of COVID-19 vaccine efficacy in older age groups. Vaccine. 2021;39:2020–2023. 10.1016/j.vaccine.2021.03.020.
    Back to article
  50. McKeigue PM, McAllister DA, Hutchinson SJ, Robertson C, Stockton D, Colhoun HM. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): A case-control study. Lancet Respir Med. 2022;10:566–572. 10.1016/S2213-2600(22)00045-5.
    Back to article
  51. Buchan SA, Chung H, Brown KA, et al. Estimated effectiveness of COVID-19 vaccines against Omicron or delta symptomatic infection and severe outcomes. JAMA Netw Open. 2022;5:e2232760. 10.1001/jamanetworkopen.2022.32760.
    Back to article
DOI: https://doi.org/10.5334/aogh.4484 | Journal eISSN: 2214-9996
Journal RSS Feed
Language: English
Submitted on: May 24, 2024
Accepted on: Jun 29, 2024
Published on: Jul 22, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
COVID-19,
vaccine efficacy,
reduction cases,
severity illness,
systematic review

© 2024 Brightwell Sibanda, Budi Haryanto, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 90 (2024): Issue 1Next article